Singapore, July 13 -- China-based startup OTR Therapeutics has entered into a strategic collaboration agreement with Korean company LG Chem to accelerate development of novel oncology therapies emerging from China.

The collaboration brings together OTR Therapeutics' proprietary R&D platform and access to China's life sciences ecosystem with LG Chem's global development expertise and commercial infrastructure.

Under the strategic framework, OTR will identify and conduct initial technical assessment of oncology programmes aligned with LG Chem's strategic priorities. Both companies will then jointly evaluate and license selected programmes.

OTR will lead preclinical and early clinical development, using China's speed, scientific infrastru...